Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

14 Nov 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2019.
14 Nov 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
14 Nov 2018 Planned initiation date changed from 15 Jun 2017 to 1 Dec 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com